Clinical and metabolic effects of dianette plus metformin and metformin only in women with polycystic ovary syndrome and metabolic disorders: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002934

Enrollment

Unknown

Registered

2012-12-29

Start date

2012-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

A:Dianette (1pill, po, 6months) and metformin (500mg, t.i.d, 6 months)

B:metformin (500mg, t.i.d, 6 months)

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Women diagnosed of PCOS; 2. BMI>=25 or fasting insulin>=20uu/ml or HOMA-IR>2.77

Exclusion criteria

Exclusion criteria: 1. Women who have the contraindication of oral contraceptive; 2. Women who have specified coexisting disease affecting the glycometabolism and lipid metabolism; 3. Women who receive hormonal therapy in the last three months; 4. Heavy smokers(>10 cigarettes/day); 5. BMI>35 kg/m2.

Design outcomes

Primary

Measure	Time frame
Insulin resistance;blood fat;Obesity related indexes;hyperandrogenic clinical manifestation;	—

Secondary

Measure	Time frame
sex hormone;blood pressure;	—

Countries

China

Contacts

Public ContactWei HUANG

xiaoqiuqiuqiuqiuqi@163.com+86 28 85501346

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026